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Abstract
Background: Infection with adeno-associated virus (AAV) vector with liver tropism leads to persistent expression of foreign
antigens in the mouse liver, with no significant liver inflammation or pathology. This provides a model to investigate
antigen persistence in the liver and strategies to modulate host immunity to reduce or clear the foreign antigen expressed
from AAV vector in the liver.
Methods/Principal Findings: We showed that expressing LIGHT with an adenovirus vector (Ad) in mice with established
AAV in the liver led to clearance of the AAV. Ad-LIGHT enhanced CD8 effector T cells in the liver, correlated with liver
inflammation. LTbR-Ig proteins blocked Ad-LIGHT in clearing AAV. Interestingly, in LTbR-null mice, Ad-LIGHT still cleared
AAV but caused no significant liver inflammation.
Conclusions/Significance: Our data suggest that LIGHT interaction with the LTbR plays a critical role in liver inflammation
but is not required for LIGHT-mediated AAV clearance. These findings will shed light on developing novel immuno-
therapeutics in treating people chronically infected with hepato-tropic viruses.
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Introduction
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV)
infection leads to liver diseases such as cirrhosis and hepatocellular
carcinoma (HCC) [1]. Similar to HBV and HCV, adeno-
associated virus (AAV) is able to establish a persistent viral
infection in the liver [2]. The mechanism of these viruses to evade
host T cell responses and persist in the liver is not clear. The
functional impairment of T cells may contribute to persistent
infection of AAV, as is observed in HBV and HCV infection in
humans [3,4].
LIGHT is a member of the TNF superfamily (TNFSF14) that
interacts with the LTbR [5] and HVEM [6] receptors. Ectopic
expression of LIGHT in the tumor induces a massive infiltration of
T cells, correlated with expression of chemokines, adhesion
molecules, and rejection of established tumors at local and distal
sites [7]. Additionally, injection of an adenoviral vector expressing
LIGHT (Ad-LIGHT) into tumor tissue leads to generation of
tumor-specific CTL and rejection of both established and
disseminated metastasizing tumor cells in the peripheral tissues
of mice [8]. Stimulation of the HVEM pathway with LIGHT
enhances co-stimulation of T cell activation [9]. By blocking the
interaction of LIGHT with the LTbR or HVEM receptors, using
a soluble HVEM-Fc or LTbR-Fc fusion protein, the allogenic T
cell responses and host-specific CTL responses are significantly
reduced [10,11].
In the liver, LTbR is expressed on Kupffer cells and may be
involved in the process of T cell tolerance induction [12].
Additionally, the LTbR is also expressed on hepatocytes, where
it contributes to liver regeneration and liver homeostasis [13]. In
transgenic mice expressing LTa-b blocking LTbR signaling
reduced inflammation in the liver [14]. Since the LIGHT/
LTbR-HVEM signaling pathway is involved in modulation of
immune responses in the liver, we investigated their function in the
liver to test whether we can induce immune activation to clear the
AAV in the liver using adenovirus-mediated LIGHT expression in
the liver.
Results and Discussion
Ad-LIGHT causes clearance of AAV genomes in the liver
We used AAV packaged with serotype 8, which is liver tropic in
vivo [15], and the U1a promoter was used to drive the expression
of GFP in transduced hepatocytes [16]. We demonstrated that
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efficiently established for at least 3 months. Therefore, AAV-U1a-
GFP established a persistent expression of GFP in the liver with no
significant liver inflammation (Fig. 1 A/B and data not shown).
The LIGHT-LTbR signaling pathway in the liver is involved in
recruiting immune cells to the liver and in liver growth regulation.
In addition, LIGHT is a potent co-stimulator of T cells. We
postulate that the T cell tolerance induced by hepatic infection of
AAV-GFP may be reversed by ectopic expression of LIGHT in
the liver. To test this hypothesis, we investigated whether we can
induce immune activation to clear the AAV-GFP using adenovi-
rus-mediated LIGHT [8] expression in the liver. First, we infected
C57/BL6 mice with AAV-GFP through the portal vein. After 18–
21 days, mice were injected with Ad-LIGHT, Ad-Ctrl vector, or
PBS. At 3–8 weeks after adenovirus injection, GFP expression and
AAV genome levels in the liver were determined. Ad-LIGHT, but
not Ad-Ctrl vector, diminished GFP expression in the AAV-GFP
expressing liver (Fig. 1C). AAV genomes in the liver were cleared,
as determined by PCR (Fig. 1D). When the LTbR-Ig fusion
protein was added to the treated mice, it blocked the ability of Ad-
LIGHT to clear AAV (Fig. 1E). These data indicate that ectopic
expression of LIGHT in the liver can lead to clearance of an
established AAV infection via interaction with LTbR.
LIGHT-mediated clearance of AAV correlates with
increased liver inflammation and CD8+ effector T cells in
the liver
In LIGHT-treated mice, a significant level of liver injury was
detected by ALT or intra-liver infiltration (Figure 2). Ad-Ctrl
Figure 1. Ad-LIGHT causes clearance of AAV infection in the liver. (A) C57BL/6 mice were injected with PBS or AAV-GFP vector. Protein was
isolated from the livers at 18 to 86 dpi. GFP protein was detected by Western blot with tubulin as a control. (B) Primers for GFP (AAV) were used to
measure AAV genomes in the liver DNA, with p18 as a host DNA control. AAV-GFP plasmid DNA was used as a positive control. H2O indicates no
template DNA control. (C–E) Mice infected with AAV-GFP for 2–3 weeks were infected with either Ad-LIGHT or Ad-Ctrl (Control) vector. Mice were
sacrificed ,4 weeks post adenovirus injection and protein or DNA was isolated from the liver. (C) Western blot for GFP and tubulin in the liver of two
mice from a representative experiment is shown. Mock or AAV-GFP only samples were included as controls. (D) Liver DNA was used to detect AAV
genomes after Ad-Ctrl (two mice) or Ad-LIGHT (3 mice) treatment. (E) Mice infected with AAV were treated with LTbR-Ig or control IgG and infected
with Ad-LIGHT or Ad-Ctrl. Liver DNA was used to detect AAV genomes. Data are representative of 4 independent experiments with 2–4 mice per
group in each experiment.
doi:10.1371/journal.pone.0010585.g001
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infected mice induced a higher ALT level than Ad-Ctrl mice
(Figure 2A). This is confirmed by an increase in the number of
leukocytes present in the liver (Figure 2B) and by the total number
of intra-hepatic leukocytes (Figure 2C). The ALT level returned to
normal around 60 dpi in both Ad-LIGHT and Ad-Ctrl infected
mice (data not shown).
To determine the immune effector cells that were stimulated by
LIGHT, leukocytes were isolated from the liver and the spleen for
analysis. We observed no increase in the percentage of
CD4+CD44+ T cells in the liver. In contrast, there was a
significant increase in the percentage of CD8+CD44+ T cells in
both the liver and spleen of mice injected with Ad-LIGHT when
compared to Ad-Ctrl (data not shown). We stimulated splenocytes
or liver leukocytes with anti-CD3. Interestingly, there was a
significant increase in the percentage of IFN-c+ CD8+ in both the
liver (Figure 3) and spleen (data not shown). LIGHT did not
enhance IFN-c expression in CD4+ cells either from the liver or
spleen (data not shown). This result is consistent with reports that
LIGHT is a co-stimulator of CD8+ T cells and causes an increase
in IFN-c production [9,17], and that OT-I CD8 T cells, when
transferred into mice with persistent Ova expression from an AAV
vector, express IFN-c and induce liver injury via activation of
Kupffer cells [18].
LTbR is not required for AAV clearance but is critical for
LIGHT-induced liver inflammation
To determine if LTbR is required for LIGHT mediated
clearance of AAV and liver injury, we tested the effect of Ad-
LIGHT in LTbR-null mice (Figure 4). Interestingly, Ad-LIGHT
led to clearance of AAV in both wild type and mutant mice,
suggesting that LTbR was not critically required for LIGHT-
mediated AAV clearance (Fig. 4A). We also examined the liver
injury and leukocyte infiltration. Ad-LIGHT infected wild type
mice showed a higher ALT level and lymphocyte infiltration than
control mice (Fig. 4B–4D). However, we observed no significant
ALT induction or leukocyte infiltration into the liver of LTbR-null
mice treated with Ad-LIGHT (Figure 4B–D). We conclude that
the LTbR is required for LIGHT-mediated liver inflammation
and injury, but a distinct signal is required for its AAV clearance
activity.
Figure 2. Ad-LIGHT induces liver inflammation. C57BL/6 mice were injected with PBS or AAV-GFP, and after 2–3 weeks injected with Ad-Ctrl or
Ad-LIGHT. (A) ALT was measured from the blood at 15 and 28 days post Adenovirus injection. Error bars indicate standard deviations. (B) Liver
sections were stained with H&E to visualize leukocyte infiltration. (C) Liver leukocytes were counted. Data are representative of 4 independent
experiments with 3–4 mice per group in each experiment. **, p,0.01.
doi:10.1371/journal.pone.0010585.g002
Figure 3. LIGHT increases CD8+ effector T cells in the liver.
C57BL/6 mice previously inoculated with AAV-GFP were injected with
Ad-Ctrl or Ad-LIGHT vector for 3–5 weeks. Leukocytes were isolated
from the liver, and stimulated with anti-CD3 (5 ug/mL) for 18 h. The
cells were then stained for surface markers and intracellular IFNc.( A)A
representative FACS plot of CD3+CD8+ T cells is shown for each group.
Numbers are % IFNc+ of CD8 T cells. (B) Summarized data are shown
from 3 independent experiments with 3–4 mice per group per
experiment. *, p,0.05.
doi:10.1371/journal.pone.0010585.g003
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AAV infection led to clearance of AAV from the liver, correlated
with elevated CD8+ effector T cells and liver injury. LTbR-Ig
proteins blocked its activity. However, the LTbR was only
required for LIGHT-induced liver injury but not for LIGHT-
mediated AAV clearance. Therefore, LIGHT mediates distinct
signals to clear AAV vectors in the liver and to induce liver
inflammation. LTbR-Ig proteins may block LIGHT interaction
with both LTbR and other receptors such as HVEM. The
interaction of LIGHT-HVEM induces co-stimulation of CD8+ T
cell activation, production of IFN-c, and modulation of T cell
responses [9,17]. Since we observed a significant increase in
effector CD8+ T cells and IFN-c in LIGHT treated mice, the
interaction of LIGHT with HVEM likely contributes to clearance
of the AAV in the liver. It has been reported that LIGHT binds to
LTbR or HVEM via distinct domains [9]. Our data suggest that it
is feasible to generate mutant LIGHT molecules that specifically
lose interaction with LTbR as novel therapeutics that can clear
liver-tropic virus without liver injury.
Materials and Methods
Mice
Male C57BL/6 mice were purchased from the Jackson
Laboratory (Bar Harbor, ME), and LTbR-null mice were
maintained at the DLAM facility at the University of North
Carolina at Chapel Hill. The project has been reviewed and
approved by the University of North Carolina at Chapel Hill
Institutional Animal Care and Use Committee (IACUC ID: 07-
114.0-B, approved on 4/13/2009).
AAV and adenovirus vectors and mouse inoculations
A self-complementary adeno-associated virus vector serotype 8
(AAV8) was kindly provided by Dr. R. Jude Samulski (Chapel Hill,
NC) and used for the construction of AAV vectors expressing
eGFP under the control of the U1a promoter were constructed.
The recombinant Ad5 (E1/E3-) adenoviral vector expressing b-
galactosidase (Ad-Ctrl) and Ad-LIGHT were generated as
described [8]. To inoculate mice, 1610
11 vp AAV were injected
Figure 4. Ad-LIGHT causes no liver injury but still clears AAV in LTbR 2/2 mice. (A) Wild type or LTbR-null mice infected with AAV-GFP
were injected with Ad-Ctrl or Ad-LIGHT. DNA from the liver was used to detect AAV genomes. Lanes 1&2= AAV2GFP + Ad-LIGHT (LTbR2/2), 3&4=
AAV2GFP + Ad-Ctrl (LTbR2/2), 5&6= AAV2GFP + Ad-LIGHT (WT), 7&8= AAV2GFP + Ad-Ctrl (WT), lane 9= mock control. (B) Wild Type (WT) and
LTbR 2/2 mice treated with AAV + Ad-LIGHT were sacrificed 3–4 weeks post adenovirus injection and liver sections stained with H&E. (C) Serum ALT
was measured 21 days after Ad-LIGHT or Ad-Ctrl injection. *, p,0.05 when compared to Ad-Ctrl treatment. (D) The livers were weighted upon
sacrifice, with an increase in liver mass in wild type but not LTbR2/2 mice treated with Ad-LIGHT. The data are representative of 2 experiments with
3 mice per group per experiment.
doi:10.1371/journal.pone.0010585.g004
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10 vp Ad-
vectors were injected intravenously 2–3 weeks after AAV
inoculation.
Antibodies
All conjugated mAb were purchased (BD Pharmingen). The JL-
8 GFP antibody was from Clontech. Anti-CD3 mAB (BD
Pharmingen) was used to stimulate T cells. LTbR-Ig was produced
as described [19,20]. Human control IgG was obtained from
Biogen Inc. LTbR-Ig or Human IgG (200 ug/kg) was injected i.p.
weekly for three weeks, once right before and twice after
adenovirus injection in AAV infected mice.
PCR, Western blotting, ALT, and liver histopathology
Serum was isolated to measure ALT levels. DNA was isolated
from ,10 mg of liver tissue using a Qiagen DNeasy kit. PCR
primers of eGFP and p18 were used to quantify relative AAV
genome. Protein was isolated from the liver for Western blot to
detect eGFP. Liver sections were fixed in 10% formalin and
paraffin sections were stained by H&E.
Cell isolation, stimulation and flow cytometry
Liver leukocytes were isolated as described [18]. Briefly, the
liver tissue suspension was treated with ACK lysis buffer to remove
red blood cells. The cells were re-suspended in 40% Percoll
(SIGMA) containing IMDM/10% FBS, loaded onto a 70%
Percoll layer, and centrifuged for 20 minutes at 3000 rpm. Cells
were stained with antibodies for CD4, CD8 and CD44. For T cell
activation, 1610
5 spleen/LN cells were stimulated with 5 ug/ml
anti-CD3 mAb for 18 h, then stained for CD4, CD8 and
intracellular cytokine (IFN-c and IL-2). Flow cytometry was
performed on a CyAn FACS machine (Dako, Carpinteria, CA).
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